Mark Voges

Mark H. Voges, Ph.D., J.D.

Patent Attorney - Member

Mark Voges’ practice focuses on patent prosecution, portfolio management and opinion work related to pharmaceuticals, chemicals, polymers, materials science, and biotechnology.

Prior to practicing patent law, Mark Voges spent five years working as a chemist and a manager for the pharmaceutical and chemical company Bayer AG. He has significant experience with regulatory compliance, chemical process design and scale-up, and plant management.

Mark is also a co-inventor of two United States patents (as well as foreign equivalents) for novel catalysts in the areas of olefin polymerization and homogeneous hydrogenation. These inventions resulted from two separate post-doctoral collaborations: (1) Brookhaven National Lab, DuPont, and the Department of Energy, (2) Borealis AS and the University of Oslo (Norway).

Experience

Mark has many years of experience developing comprehensive patent prosecution and portfolio management strategies for chemical and pharmaceutical-based inventions. His experience extends from catalysts, polymers, and biomolecules to the full range of pharmaceutical inventions, including new chemical entities, enantiomers and other stereoisomers, polymorphic forms, second medical uses, formulations, dosage regimes, and personalized medicine. Important practice considerations for pharmaceutical inventions include maximizing patent protection for the active pharmaceutical ingredient (API) after regulatory approval has been obtained. As such Mark is frequently called upon to provide advice at the interface between patent law and FDA law, including Orange Book listings, Hatch Waxman patent term extension, data exclusivity, skinny labeling carve-outs and ANDA litigation.

Prior to joining Parker Highlander, Mark spent 6 years practicing at Fulbright & Jaworski’s Intellectual Property Group’s Austin office. And prior to becoming a patent lawyer, Mark spent five years working as a chemist and a manager for the pharmaceutical and chemical company Bayer AG in Germany, where he has gained significant experience with regulatory compliance for pharmaceuticals (good manufacturing practices—GMP), chemical process design and scale up, plant management, and structure-based chemical database searching (STN).

Mark is a co-inventor of two United States patents (as well as foreign equivalents) for novel catalysts in the areas of olefin polymerization and homogeneous hydrogenation. These inventions resulted from two separate post-doctoral collaborations: 1) Brookhaven National Lab, DuPont, and the Department of Energy, 2) Borealis AS and the University of Oslo (Norway).

Professional Activities & Memberships

  • American Chemical Society
  • Licensed to Practice before the U.S. Patent and Trademark Office
  • State Bar of Texas
  • American and Austin Intellectual Property Law Associations

Professional Honors

  • Texas Super Lawyer’s Magazine – Rising Star for 2014

Publications

  • Co-Author with S.L. Highlander, “‘Reference Composition’ not ‘Lead Compound’: Recent Developments in Case Law for Obviousness of Pharmaceutical Composition Claims,” Pharm. Pat. Analyst, 2012, 1(4), 385-92.
  • Co-Author with P. J. Fagan and R. M. Bullock, “Catalytic Ionic Hydrogenation of Ketones by {[Cp*Ru(CO)2]2(µ-H)}+,” Organometallics, 2010, 29(4), 1045-48.
  • Co-Author with R. M. Bullock, “Catalytic Ionic Hydrogenations of Ketones Using Molybdenum and Tungsten Complexes,” J. Chem. Soc., Dalton Trans., 2002, 759-70.
  • Co-Author with R. M. Bullock, “Homogeneous Catalysis with Inexpensive Metals: Ionic Hydrogenation of Ketones with Molybdenum and Tungsten Catalysts,” J. Am. Chem. Soc., 2000, 122(50), 12594-95.
  • Co-Author with C. Romming and M. Tilset, “Synthesis and Characterization of 14-Electron Cyclopentadienyl Chromium(II) Complexes Containing a Heterocyclic Carbene Ligand,” Organometallics, 1999, 18(4), 529-33.
  • Co-Author with D. M. Heinekey, C. E. Radzewich, B. M. Schomber, “Cationic Hydrogen Complexes of Rhenium. 2. Synthesis, Reactivity, and Competition Studies,” J. Am. Chem. Soc., 1997, 119(18), 4172-81.
  • Co-Author with D. M. Heinekey, D. M. Barnhart, “Rhenium Dihydrogen Complexes with Isonitrile Coligands: Novel Displacement of Chloride by Hydrogen,” J. Am. Chem. Soc., 1996, 118(44), 10792-802.
  • U.S. Patent No. 6,613,851, issued September 2, 2003, Jens, Klaus-Joachim; Morten, “Catalyst for the polymerization of olefins.”
  • U.S. Patent No. 6,124,509, issued September 26, 2000, Voges, Mark; Bullock, R. Morris, “Catalytic ionic hydrogenation of ketones using tungsten or molybdenum organometallic species.”

Educational Background

  • 2006 – J.D., with honors, The University of Texas School of Law
  • 1996 – Ph.D., Chemistry, University of Washington, Seattle
  • 1991 – B.A., magna cum laude, Chemistry and German, Bowdoin College, Maine
  • While in law school, Mark served as a Chief Articles Editor for the Texas Intellectual Property Law Journal.

Language Capabilities

  • German – Fluent